Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-109 (levosimendan) for respiratory function in ALS
NL-OMON42507Phase 2Active, not recruiting
- Sponsor
- Orion Corporation
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of levosimendan in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Orion Corporation. Primary endpoint: Upright slow vital capacity. Started Dec 2015; status: active, not recruiting.
02
Drugs
levosimendan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON42507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42507.